ABBVIE
Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine
- Conditions
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 1000
- Registration Number
- NCT06543914
- Locations
- 🇺🇸
Neurology and Neurodiagnostics of Alabama /ID# 267614, Hoover, Alabama, United States
🇺🇸Kenneth Martinez MD, A Medical Corp /ID# 267834, Aliso Viejo, California, United States
🇺🇸Los Angeles Headache Center /ID# 267570, Los Angeles, California, United States
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
- First Posted Date
- 2024-07-29
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 60
- Registration Number
- NCT06524635
- Locations
- 🇺🇸
University of Michigan Health System - Ann Arbor /ID# 267275, Ann Arbor, Michigan, United States
🇺🇸Physioseq, LLC /ID# 267266, Sacramento, California, United States
A Study to Assess Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization in Chinese Participants Receiving Upadacitinib for Atopic Dermatitis (AD) Through Chart Review
- Conditions
- First Posted Date
- 2024-07-16
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 150
- Registration Number
- NCT06503536
- Locations
- 🇨🇳
Huashan Hospital affiliated to Fudan University /ID# 268259, Shanghai, Shanghai, China
A Study to Assess Pharmacokinetic Exposures Following Intravenous and Subcutaneous Administration of Risankizumab in Healthy Participants
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 60
- Registration Number
- NCT06487572
- Locations
- 🇺🇸
Clinical Pharmacology Of Miami /ID# 268219, Miami, Florida, United States
🇺🇸Acpru /Id# 267057, Grayslake, Illinois, United States
A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)
- Conditions
- Interventions
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 20
- Registration Number
- NCT06487559
- Locations
- 🇨🇳
Hubei Cancer Hospital /ID# 262030, Wuhan, Hubei, China
🇨🇳Zhejiang Cancer hospital /ID# 262046, Hangzhou, Zhejiang, China
🇨🇳Mengchao Hepatobiliary Hospital of Fujian Medical University /ID# 262443, Fuzhou, Fujian, China
A Study to Assess Relative Bioavailability and Food Effect of ABBV-668 Extended-Release Formulations in Adult Participants
- First Posted Date
- 2024-06-27
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 25
- Registration Number
- NCT06477926
- Locations
- 🇺🇸
Acpru /Id# 266960, Grayslake, Illinois, United States
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
- First Posted Date
- 2024-06-21
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 1280
- Registration Number
- NCT06468228
- Locations
- 🇨🇳
Linkou Chang Gung Memorial Hospital /ID# 264620, Taoyuan City, Taiwan
🇨🇳National Taiwan University Hospital /ID# 264618, Taipei City, Taipei, Taiwan
🇨🇳Mackay Memorial Hospital /ID# 263661, Taipei City, Taiwan
Study to Assess Adverse Events and How Intravenously (IV) Infused ABBV-400 Moves Through the Body of Adult Participants With Unresectable Locally Advanced/Metastatic Colorectal Cancer
- First Posted Date
- 2024-06-18
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 27
- Registration Number
- NCT06464692
- Locations
- 🇨🇳
The Sixth Affiliated Hospital of Sun Yat-sen University /ID# 263309, Guangzhou, Guangdong, China
🇨🇳First Affiliated Hospital of China Medical University /ID# 263338, Shenyang, Liaoning, China
🇨🇳Beijing Cancer Hospital /ID# 263297, Beijing, Beijing, China
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
- First Posted Date
- 2024-06-17
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 675
- Registration Number
- NCT06461897
- Locations
- 🇺🇸
Medical University of South Carolina /ID# 265113, Charleston, South Carolina, United States
🇬🇧Chelsea and Westminster Hospital /ID# 266389, London, Greater London, United Kingdom
🇺🇸Integrative Skin Science and Research /ID# 265108, Sacramento, California, United States
Study of Oral Upadacitinib to Assess Change in Disease Activity and Adverse Events in Adult Participants With Ulcerative Colitis or Crohn's Disease
- Conditions
- First Posted Date
- 2024-06-14
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 600
- Registration Number
- NCT06459297
- Locations
- 🇰🇷
The Catholic University of Korea, Seoul St. Marys Hospital /ID# 270014, Seoul, Seoul Teugbyeolsi, Korea, Republic of
🇰🇷SoonChunHyang University Hospital Cheonan /ID# 270015, Cheonan-si, Chungcheongnamdo, Korea, Republic of
🇰🇷The Catholic University of Korea, Daejeon St. Mary's Hospital /ID# 267843, Daejeon, Daejeon Gwang Yeogsi, Korea, Republic of